Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses
Recruiting at 7 trial locations
AC
Overseen ByAlcon Call Center
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Alcon Research
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix plus HydraGlyde Multifocal soft contact lenses in a real-world setting when worn as daily wear or extended (overnight) wear.
Research Team
CT
Clinical Trial Lead, Vision Care
Principal Investigator
Alcon Research, LLC
Eligibility Criteria
Inclusion Criteria
Best Corrected Visual Acuity (BCVA) of 20/25 Snellen or better in each eye at baseline;
Must have worn or be wearing Air Optix plus Hydraglyde Multifocal or Biofinity Multifocal for at least 1 year in a daily wear modality, or 3 years in an extended wear modality;
Other protocol-defined inclusion criteria may apply.
Treatment Details
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Biofinity Multifocal Extended WearExperimental Treatment1 Intervention
Comfilcon A multifocal soft contact lenses worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
Group II: Biofinity Multifocal Daily WearExperimental Treatment1 Intervention
Comfilcon A multifocal soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
Group III: Air Optix plus HydraGlyde Multifocal Extended WearExperimental Treatment1 Intervention
Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).
Group IV: Air Optix plus HydraGlyde Multifocal Daily WearExperimental Treatment1 Intervention
Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alcon Research
Lead Sponsor
Trials
739
Recruited
128,000+
Raquel C. Bono
Alcon Research
Chief Medical Officer since 2022
MD from Harvard Medical School
David Endicott
Alcon Research
Chief Executive Officer since 2018
MBA from University of Southern California
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.